221 related articles for article (PubMed ID: 37120552)
21.
Chiang YC; Park IY; Terzo EA; Tripathi DN; Mason FM; Fahey CC; Karki M; Shuster CB; Sohn BH; Chowdhury P; Powell RT; Ohi R; Tsai YS; de Cubas AA; Khan A; Davis IJ; Strahl BD; Parker JS; Dere R; Walker CL; Rathmell WK
Cancer Res; 2018 Jun; 78(12):3135-3146. PubMed ID: 29724720
[TBL] [Abstract][Full Text] [Related]
22. Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Tong P; Wang J; Castle EP; Stanton ML; Cheville JC; Jonasch E; Brugarolas J; Parker AS
Mod Pathol; 2016 Jan; 29(1):34-42. PubMed ID: 26516698
[TBL] [Abstract][Full Text] [Related]
23. Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.
Liu Q; Jin J; Ying J; Sun M; Cui Y; Zhang L; Xu B; Fan Y; Zhang Q
Int J Mol Sci; 2015 May; 16(5):10636-49. PubMed ID: 25970749
[TBL] [Abstract][Full Text] [Related]
24. Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma.
Takeda K; Bastacky S; Dhir R; Mohebnasab M; Quiroga-Garza GM
Ann Diagn Pathol; 2024 Feb; 68():152223. PubMed ID: 37976977
[TBL] [Abstract][Full Text] [Related]
25. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
Liao L; Testa JR; Yang H
Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
[TBL] [Abstract][Full Text] [Related]
26. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
[TBL] [Abstract][Full Text] [Related]
27. PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links multiple pathways.
Feng C; Sun Y; Ding G; Wu Z; Jiang H; Wang L; Ding Q; Wen H
Sci Rep; 2015 Apr; 5():9465. PubMed ID: 25853938
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma.
Jiang W; Dulaimi E; Devarajan K; Parsons T; Wang Q; O'Neill R; Solomides C; Peiper SC; Testa JR; Uzzo R; Yang H
Oncotarget; 2017 Jun; 8(23):37423-37434. PubMed ID: 28445125
[TBL] [Abstract][Full Text] [Related]
29. Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation.
Feng C; Ding G; Jiang H; Ding Q; Wen H
Tumour Biol; 2015 May; 36(5):3457-64. PubMed ID: 25528216
[TBL] [Abstract][Full Text] [Related]
30. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
31. The Identification of Zinc-Finger Protein 433 as a Possible Prognostic Biomarker for Clear-Cell Renal Cell Carcinoma.
Heyliger SO; Soliman KFA; Saulsbury MD; Reams RR
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439859
[TBL] [Abstract][Full Text] [Related]
32. Deciphering intratumor heterogeneity in clear cell renal cell carcinoma utilizing clinicopathologic and molecular platforms.
Vormittag-Nocito E; Mannan R; Wang X; Chinnaiyan A; Zhang Y; Zelenka-Wang S; Cao X; Morgan TM; Hafez K; Vaishampayan U; Abdulfatah E; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Hum Pathol; 2022 Dec; 130():95-109. PubMed ID: 36511267
[TBL] [Abstract][Full Text] [Related]
33. Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level.
Manini C; López-Fernández E; Lawrie CH; Laruelle A; Angulo JC; López JI
Curr Urol Rep; 2022 Jun; 23(6):93-97. PubMed ID: 35416538
[TBL] [Abstract][Full Text] [Related]
34. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
[TBL] [Abstract][Full Text] [Related]
35. Development of a SETD2-related immune prognostic signature in clear cell renal cell carcinoma.
Wang X; Xia Z; Li Z; Zhang C
Medicine (Baltimore); 2022 Aug; 101(31):e29561. PubMed ID: 35945780
[TBL] [Abstract][Full Text] [Related]
36. SETD2: an epigenetic modifier with tumor suppressor functionality.
Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
[TBL] [Abstract][Full Text] [Related]
37. Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinoma.
Zhao J; Liang J; Yang Y; Sun G; Zhang X; Zhao J; Hu X; Chen J; Zhu S; Ni Y; Zhang Y; Dai J; Wang Z; Wang Z; Zeng Y; Yao J; Chen N; Shen P; Liu Z; Zeng H
Clin Epigenetics; 2022 Aug; 14(1):99. PubMed ID: 35941663
[TBL] [Abstract][Full Text] [Related]
38. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint.
Carvalho S; Vítor AC; Sridhara SC; Martins FB; Raposo AC; Desterro JM; Ferreira J; de Almeida SF
Elife; 2014 May; 3():e02482. PubMed ID: 24843002
[TBL] [Abstract][Full Text] [Related]
39. A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation.
Javaid H; Barberis A; Chervova O; Nassiri I; Voloshin V; Sato Y; Ogawa S; Fairfax B; Buffa F; Humphrey TC
BMC Cancer; 2023 Aug; 23(1):721. PubMed ID: 37528416
[TBL] [Abstract][Full Text] [Related]
40. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
